On September 27, 2021 INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported that Mark Lowdell, PhD, Chief Scientific Officer and Chief Medical Officer, will be participating in an oncology panel at the B. Riley Fall 2021 Best Ideas in Oncology Series (Press release, INmune Bio, SEP 27, 2021, View Source [SID1234590294]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel details:

Title: Improving Strategies to Harness the Immune System

Date: Thursday, September 30, 2021

Time: 9:00am ET

This event is open to institutional investors. Interested parties may register for the panel here.